Tel Aviv, Israel – August 28, 2026
Teva Pharmaceutical Industries announced that it has entered into an agreement to serve as the stalking horse bidder for certain assets of BioXcel Therapeutics, including BXCL501 (dexmedetomidine sublingual film), through a court-supervised Chapter 11 sale process. BXCL501 is currently under U.S. FDA review for potential at-home use in the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The FDA has assigned a PDUFA target action date of November 14, 2026. Under the proposed transaction, Teva would acquire worldwide rights to the asset for an upfront payment of $57.5 million, plus up to $67.5 million in contingent payments tied to regulatory timing and specified sales milestones. The transaction remains subject to bankruptcy court approval, potential higher bids and customary closing conditions. If approved for at-home use, the product could potentially become the first FDA-approved at-home treatment for agitation associated with schizophrenia or bipolar disorder.
Teva Targets BXCL501 to Strengthen Its Neuroscience Portfolio
The proposed transaction would give Teva worldwide rights to dexmedetomidine sublingual film, an orally dissolving film formulation of the selective alpha-2 adrenergic receptor agonist dexmedetomidine. The asset is being evaluated for acute treatment of agitation in adults with schizophrenia or bipolar I or II disorder in an outpatient or at-home setting. Teva is pursuing the asset as part of its broader Pivot to Growth strategy, emphasizing targeted business development opportunities with strategic fit and potential long-term value. The proposed acquisition does not involve buying BioXcel Therapeutics as a company; instead, Teva would acquire specified assets through the bankruptcy sale process. Teva’s stalking-horse bid establishes the initial offer for the assets, but another bidder could ultimately be selected through the court-supervised auction
BXCL501 Awaits FDA Decision for Potential At-Home Use
The key development opportunity is the potential expansion of dexmedetomidine sublingual film from supervised healthcare use into an at-home acute treatment option. The FDA is currently reviewing the product, with a November 14, 2026 PDUFA target date. If approved for the proposed indication, the therapy could address a significant treatment gap because acute agitation can lead to emergency department visits, hospitalization or escalation of care, while currently available treatment options are often administered in healthcare settings. The underlying product, IGALMI®, is already approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, but its current use requires administration under the supervision of a healthcare provider. The proposed transaction therefore centers on the potential value of expanding the product’s setting of use rather than acquiring an entirely unvalidated clinical asset.
Advertisement
Hopledo Targets Longer Symptom Control With Fewer Daily Doses
Under the agreement, Teva would pay $57.5 million upfront if it ultimately becomes the successful bidder and the transaction closes. The company could pay an additional up to $67.5 million in contingent consideration, including payments linked to the timing of FDA approval and specified commercial sales milestones. The structure limits Teva’s immediate financial exposure while retaining the opportunity to participate in the asset’s potential value if regulatory and commercial objectives are achieved. However, the acquisition is not yet completed. The transaction must proceed through BioXcel’s Chapter 11 sale process, receive bankruptcy court approval and satisfy other closing conditions, and competing bids may emerge. For Teva, the strategic upside depends heavily on the FDA’s November 2026 decision and the potential commercial adoption of an at-home treatment model for acute agitation.
Source: Teva, press relese
